-+ 0.00%
-+ 0.00%
-+ 0.00%

uniQure Q3 net loss narrows 24% to USD 61.22 million

PUBT·11/04/2026 12:16:26
Listen to the news
uniQure Q3 net loss narrows 24% to USD 61.22 million
  • uniQure’s third-quarter 2026 net loss narrowed 24% year over year to $61.22 million.
  • Revenue rose 40% year over year to $5.2 million due to higher license revenue.
  • Cash, cash equivalents and investment securities totaled $768.4 million at September 30, 2026, sufficient to fund projected operating expenses into 2030.
  • The FDA granted priority review to AMT-130 for Huntington’s disease, with a May 1, 2027, target action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040705OMX_____CNEWS_EN_GNW9869649_en) on November 04, 2026, and is solely responsible for the information contained therein.